Hyperliquid Labs, registered in Singapore, is considered unregulated by the Monetary Authority of Singapore (MAS) because of its decentralized structure. MAS added Hyperliquid to its crypto warning list, signaling that it does not have jurisdiction over the platform, which has never sought or claimed MAS authorization. Hyperliquid offers perpetual futures, a high-risk crypto derivative product, and highlights the ongoing challenge of regulating decentralized platforms. This regulatory ambiguity complicates institutional investment and raises questions about jurisdiction in the crypto industry.
Hyperliquid and MAS regulatory clash provides context for crypto market trends. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 07, 2026 17:22 WIB: Out of 50 major cryptocurrencies, 6 rose and 43 fell. Notable movers include EGLD at Rp72.757 down 9.87%, DOT at Rp19.951 down 9.32%, and SAND at Rp1.287 up 9.18%.
Diebold Nixdorf will release its third quarter 2026 financial results on October 28 before the NYSE opens. CEO Octavio Marquez and CFO Tom Timko will discuss the results in a conference call and webcast starting at 8:30 a.m. ET the same day. The comp...
In response to a measles outbreak and statewide emergency in New York, CVS Health is offering measles-mumps-rubella (MMR) vaccinations at over 530 CVS Pharmacy locations and MinuteClinic sites across the state. The MMR vaccine is crucial to prevent t...
FirstService Residential, a leading property management company in New York, was honored as Property Management Firm of the Year at the 17th RED Residential Real Estate Awards. This award recognizes the company's excellence in service, leadership, an...
On October 7, Mantle (MNT) experienced a notable increase in trading volume and derivatives activity, with open interest dropping 14% to $50 million and derivatives volume rising 210% to $39 million. Spot trading volume also grew by 89% to $48 millio...
Eli Lilly's most profitable stock entry points were during less hyped events like the 2008 ImClone acquisition and the 2014 Trulicity approval, yielding returns over 2,000%. In contrast, buying at the peaks of hype around blockbuster drugs Mounjaro a...
